Series A · Biotech · Cambridge, United Kingdom · Founded 2016 · 51–200 employees
bit.bio is a Cambridge University spinout that has developed opti-ox, a proprietary precision cell programming technology that can reprogram human stem cells into any mature cell type with unprecedented consistency and at industrial scale. The company raised $41.5 million in Series A funding from leading US life science investors including Rick Klausner, former US National Cancer Institute Director. Their technology enables the production of human cells for research, drug discovery and cell therapy, addressing the critical shortage of human cells that hampers medical research and makes cell therapies expensive.
No open roles listed right now.